Journal
ANTIVIRAL THERAPY
Volume 16, Issue 2, Pages 257-261Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1749
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- NATIONAL CANCER INSTITUTE [ZIABC010820] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001121] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available